drastically alter how medical professionals and the general public approach weight loss.
In instance, three medications—marketed under the trade names Wegovy, Ozempic,
and Mounjaro—have demonstrated notable impacts on weight loss in clinical studies.
The other two medications, though they also significantly aid in weight loss,
are only permitted as treatments for type 2 diabetes, in contrast to Wegovy,
which is permitted for weight loss by the Food and Drug Administration.
Due to an increase in demand, Ozempic and Mounjaro became scarce in early 2023,